Our resources

Peer-Reviewed Papers

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
Trial Analysis
Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
READ MORE →
 Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit
Trial Analysis
Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit
READ MORE →
 The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Trial Analysis
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
READ MORE →
 An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
Trial Analysis
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
READ MORE →